FiercePharma

NEW TECFIDERA® (DIMETHYL FUMARATE) DATA SHOW SUSTAINED EFFICACY AND LONG-TERM SAFETY IN A BROAD RANGE OF MULTIPLE SCLEROSIS PATIENTS

WESTON, Mass.--(BUSINESS WIRE)--Oct. 4, 2013-- Data presented today show that TECFIDERA® (dimethyl fumarate) continues to offer consistent and strong efficacy combined with a favorable safety profile ...
Monthly Prescribing Reference

Tecfidera: Positive Data from Three Phase 3 Studies

TECFIDERA (dimethyl fumarate) 120mg and 240mg delayed-release caps by Biogen Idec Biogen presented new data at ECTRIMS showing that Tecfidera (dimethyl fumarate) significantly reduced multiple ...
Yahoo Finance

Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis

CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that China’s National Medical Products Administration (NMPA) has approved TECFIDERA ® (dimethyl fumarate ...
News Medical

Interim data from long-term extension Tecfidera® (dimethyl fumarate) study

Biogen (NASDAQ: BIIB) will, this week, present data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, demonstrating the ...
Nasdaq

New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years

CAMBRIDGE, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new data to support the consistent, long-term benefits of treatment with TECFIDERA® (dimethyl fumarate) over ...
FiercePharma

TECFIDERA (Dimethyl Fumarate) Approved in the European Union as a First-Line Oral Treatment for Multiple Sclerosis

Biogen Idec to Begin Launching TECFIDERA in Initial EU Countries in the Coming Weeks CAMBRIDGE, Mass.--(BUSINESS WIRE)-- TECFIDERA® (dimethyl fumarate) has been approved by the European Commission (EC ...
FierceBiotech

CHMP Issues Positive Opinion for TECFIDERA™ (Dimethyl Fumarate) as a First-Line Treatment for Multiple Sclerosis in the European Union

CHMP Issues Positive Opinion for TECFIDERA™ (Dimethyl Fumarate) as a First-Line Treatment for Multiple Sclerosis in the European Union WESTON, Mass.--Mar. 22, 2013-- Today Biogen Idec (NASDAQ: BIIB) ...
Yahoo Finance

European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate)

Patent covers approved dosing regimen for TECFIDERA and expires in 2028 CAMBRIDGE, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Patent Office ...
Business Wire

Biogen Idec’s TECFIDERA™ (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis

- Offers a Broad Spectrum of Patients with Relapsing Forms of MS an Effective and Convenient Treatment Option - WESTON, Mass.--(BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) announced that the U.S.
Chicago Tribune

Woman Learns To Embrace Life With Relapsing Multiple Sclerosis (MS)

As a grandmother of two young boys, Pam Hill values the time she spends with her family more than anything. She helps care for her one-year-old grandson almost every day, and while she cherishes their ...
Finanznachrichten

Biogen Inc.: Biogen Grows Presence in China with the Approval of TECFIDERA (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis

About TECFIDERA (dimethyl fumarate) TECFIDERA, a treatment for relapsing forms of multiple sclerosis (MS) in adults, is the most prescribed oral medication for relapsing MS in the world and has been ...